Why AI-Powered MedTech Needs Better Evidence, Not Just Better Algorithms

Artificial intelligence is transforming the MedTech sector.
AI-powered technologies are now being used in diagnostics, imaging, remote monitoring, triage, clinical decision support, and workflow automation. Many of these tools promise faster diagnosis, more efficient care, and better patient outcomes.
However, as AI becomes more common in healthcare, expectations are also changing.
For many years, companies focused heavily on algorithm performance. Metrics such as sensitivity, specificity, accuracy, and predictive value were often seen as the main indicators of success.
Today, this is no longer enough.
Healthcare systems, HTA bodies, and payers increasingly want to know whether AI technologies provide meaningful value in real clinical settings.
Technical Accuracy Does Not Automatically Mean Clinical Value
A highly accurate algorithm may still fail to deliver value if it does not improve decision-making or patient outcomes.
For example, an AI diagnostic tool may identify abnormalities more quickly than clinicians, but if it does not reduce delays, improve treatment decisions, or improve outcomes, its value may remain limited.
Similarly, an AI solution that produces too many false positives may increase unnecessary follow-up tests, increase workload, and create extra costs for healthcare providers.
Clinical performance is important, but it is only one part of the value story.
Decision-makers increasingly want to understand:
• Does the technology improve outcomes?
• Does it support earlier diagnosis?
• Does it reduce complications or hospitalisations?
• Does it improve workflow efficiency?
• Does it save clinician time?
• Does it reduce healthcare costs?
Without evidence in these areas, even strong algorithms may struggle to achieve adoption.
Real-World Evidence Is Becoming More Important
Many AI solutions perform well in controlled development environments but less well in real-world clinical settings.
This may happen because:
• Patient populations differ from the original training dataset
• Clinical workflows vary between hospitals
• Data quality is inconsistent
• Local practices influence how the technology is used
• Clinicians may not fully trust or adopt the tool
As a result, payers and providers increasingly want real-world evidence in addition to technical validation studies.
Real-world evidence can help demonstrate:
• How the technology performs in everyday practice
• Whether clinicians actually use it
• Whether it improves efficiency
• Whether it changes treatment decisions
• Whether it reduces resource use or costs
For AI-powered MedTech companies, real-world evidence is becoming a critical part of reimbursement and adoption discussions.
Clinical Utility Matters More Than Algorithm Performance
One of the biggest mistakes companies make is focusing too heavily on algorithm accuracy while overlooking clinical utility.
Clinical utility refers to whether the technology changes patient management in a meaningful way.
For example, an AI tool may detect lung nodules more accurately than a radiologist, but its real value depends on whether it:
• Leads to earlier cancer detection
• Reduces missed diagnoses
• Improves survival
• Reduces unnecessary biopsies
• Supports better treatment decisions
Healthcare systems are not paying for algorithms. They are paying for better outcomes and more efficient care.
Companies that can demonstrate clear clinical utility are often in a much stronger position when discussing reimbursement and market access.
Economic Evidence Is Also Essential
AI technologies are often promoted as cost-saving tools, but these claims need evidence.
Payers increasingly want to understand:
• Whether the technology reduces healthcare costs
• Whether it lowers hospital admissions
• Whether it reduces staff workload
• Whether it avoids unnecessary tests or procedures
• Whether it provides good value for money
In some cases, AI may improve clinical performance but still increase overall costs.
For example, a highly sensitive diagnostic tool may identify more patients, but it may also increase referrals, imaging use, or follow-up testing.
Economic modelling and health economic evidence are therefore becoming more important for AI-powered MedTech products.
Trust, Transparency, and Explainability Are Growing Concerns
Many healthcare providers remain cautious about using AI systems they do not fully understand.
Clinicians are often more likely to adopt technologies that are transparent and explainable.
Questions may include:
• How does the algorithm reach its conclusions?
• Can clinicians understand the reasoning?
• How often is the model updated?
• Does performance remain stable over time?
• Is there a risk of bias in certain patient groups?
Trust is particularly important in high-risk areas such as oncology, diagnostics, and critical care.
Companies that address transparency and explainability early may have an advantage over those that rely only on performance metrics.